Kenneth L. Londoner

Kenneth L. Londoner is the founder, chairman, and CEO of BioSig Technologies. Kenneth has also served on the board of directors for Alliqua, Inc. from May 2012 to February 2014. Alliqua is a biomedical company that specialized in drug delivery via its FDA approved hydrogel platform. Its first product, SilverSeal, is a wet wound care dressing infused with sterile silver that provides clinical advantages for better and more cost effective patient care. The Company recently (November 2013) consummated a strategic relationship with Celgene, who took a significant investment position in the Company. Alliqua was just listed January 28, 2014 on the Nasdaq under ticker symbol Nasdaq: ALQA.

Previously, Londoner was a business partner and investor for Inspire MD, Ltd. from July 2010 to February 2013. InspireMD is an Israeli medical device developer that has invented a novel bare metal stent that is best used for Acute MI and has been successfully used in over 13,000 procedures in over 47 countries. The Company is working on getting FDA approval so they can offer U.S. patients the benefits of their advanced stent technology. The Company recently became a publicly traded entity under the symbol NSPR.

Kenneth L. Londoner is a Visiting Professor at Columbia Business School and the founder of InternShift, an advanced Internship Program. Kenneth has an MBA in Economics and Management from NYU Stern School of Business, and a degree in Economics from Lafayette College.

Zachary Koch - Clinical Director, Gray Fleming - Chief Commercial Officer, and Steve Chaussy - Chief Financial Officer report to Kenneth L. Londoner.